Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
about
Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifenePatient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifeneThe discovery and development of selective estrogen receptor modulators (SERMs) for clinical practiceLasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophyThe effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeletonAn innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals.New selective estrogen and androgen receptor modulatorsLasofoxifene: Evidence of its therapeutic value in osteoporosis.Selective estrogen receptor modulators: tissue specificity and clinical utility.From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).Treatment of osteopenia.Designing the ideal selective estrogen receptor modulator--an achievable goal?SERMs in the prevention and treatment of postmenopausal osteoporosis: an update.New treatment modalities in osteoporosis.Progress in endocrine approaches to the treatment and prevention of breast cancerEmerging pharmacologic therapies for osteoporosis.A new approach to menopausal therapy: the tissue selective estrogen complex.Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.New horizons in treatment of osteoporosis.Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.SERMs and SERMs with estrogen for postmenopausal osteoporosis.Osteoporosis update: effective prevention and treatment.Current, new and future treatments of osteoporosis.Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.Osteoporosis and osteopenia: implications for periodontal and implant therapy.New developments in the treatment of osteoporosis.Emerging hormonal treatments for menopausal symptoms.Emerging drugs for the treatment of bone metastasis.Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis.Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of "Lasofoxifene in postmenopausal women with osteoporosis". N Engl J Med 2010;362:686-96.Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes.Tissue selective estrogen complex (TSEC): a review.
P2860
Q24652524-878EB423-F447-4140-8527-154EAF12AB0EQ26751149-6BF36567-3152-46C2-AEA3-2C7378D12E36Q26830744-1564630F-7810-43DA-B7DF-AEF30AFCDADEQ28253298-4F56265D-D496-4431-B5CF-1608020FA1AFQ28539057-88E2D565-AE5B-4188-AF21-5E03AF6C0298Q33780223-D2445EFC-A8AB-4CD7-A44D-50F32AA0C8E9Q33814078-49665AE6-F59D-418E-AEBE-C200DED47EB7Q33973891-0CCD3360-377A-4CC4-976E-C6177D8CEB13Q34134828-EB7583E9-F9BF-410A-AB15-479F2600848AQ34315413-0AB6BF3B-8B68-4E8F-BA06-148F58A62436Q34630644-920EBCCB-ABFD-412B-AF94-F72C5961FF90Q35023776-04418036-9BC8-4886-A3D9-49209E0EA0E0Q35028647-0AF43556-3723-4FAE-9D6E-A4ECF00B3757Q35754801-E3A6572F-1F14-4ED8-83FD-FEDE495EA90CQ36457511-C3064A59-20D3-4549-95E9-19C429222D99Q36944034-953CEAD1-B38D-4C48-9BFE-BB62A524A425Q37352516-FD3F4E81-CBB8-42E5-9949-EB87AC7C6FF8Q37412956-66C95E5E-F287-4A02-8A1C-B7FF01C34BBBQ37630995-0D54A249-F3B5-4B5C-9499-A7DD6404CCB8Q37677579-FE98EE49-BB22-4843-9851-BB7988C43706Q37743272-9B32E398-D6D9-4402-A572-411EF953D740Q37763162-24663447-F0CE-4B21-BF7C-8E24F6ADA882Q37777053-425B2BE1-36E3-4FEF-A63A-A7816A1877D7Q37861982-9FF7C91A-32FC-49D7-A665-894F6A84BC41Q38002942-176562E3-B0FA-4411-A64E-0440A3A99733Q38014515-F678AF0F-4E77-40D6-91E6-7481DAB22533Q38307019-09AEE488-7DD7-4861-95E8-E7DF07FA0029Q38538263-790FF67D-2D6F-4AD0-9691-F3F6C0EAA353Q39788803-C31E20DB-5244-4419-B982-1300EEE95477Q42836293-48127F27-31F0-42CB-B727-474CC3B2CC38Q43072115-F87C84BC-AE36-4F57-B9A1-77BF5CB7F594Q44312736-B4702B22-6BFB-4A7E-B781-BEB6F97BDAC2Q53837780-841A7189-41D5-4DB0-9EC8-E5CEAF796153
P2860
Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Prevention of bone loss in pos ...... fene compared with raloxifene.
@ast
Prevention of bone loss in pos ...... fene compared with raloxifene.
@en
Prevention of bone loss in pos ...... fene compared with raloxifene.
@nl
type
label
Prevention of bone loss in pos ...... fene compared with raloxifene.
@ast
Prevention of bone loss in pos ...... fene compared with raloxifene.
@en
Prevention of bone loss in pos ...... fene compared with raloxifene.
@nl
prefLabel
Prevention of bone loss in pos ...... fene compared with raloxifene.
@ast
Prevention of bone loss in pos ...... fene compared with raloxifene.
@en
Prevention of bone loss in pos ...... fene compared with raloxifene.
@nl
P2093
P1433
P1476
Prevention of bone loss in pos ...... fene compared with raloxifene.
@en
P2093
Alfred Moffett
Andrew Lee
Ethel Siris
Mark Ettinger
Michael Bolognese
Michael R McClung
Ronald Emkey
Steve Cummings
Veena Somayaji
Wesley Day
P304
P356
10.1097/01.GME.0000188736.69617.4F
P407
P577
2006-05-01T00:00:00Z